These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1606562)

  • 21. [Periodical screening of families with a hereditary predisposition for breast carcinoma].
    Vasen HF; Devilee P
    Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2350-4. PubMed ID: 8264817
    [No Abstract]   [Full Text] [Related]  

  • 22. Collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome.
    Li FP; Fraumeni JF
    Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):715-7. PubMed ID: 7881346
    [No Abstract]   [Full Text] [Related]  

  • 23. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals.
    Li FP; Garber JE; Friend SH; Strong LC; Patenaude AF; Juengst ET; Reilly PR; Correa P; Fraumeni JF
    J Natl Cancer Inst; 1992 Aug; 84(15):1156-60. PubMed ID: 1635084
    [No Abstract]   [Full Text] [Related]  

  • 26. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor diseases in families of 600 breast cancer patients with special reference to familial adenocarcinomatosis and the Li-Fraumeni-/SBLA syndrome].
    Müller H; Mosimann S; Gebhardt M; Scott R; Spycher M; Weber W
    Helv Chir Acta; 1992 May; 59(1):239-45. PubMed ID: 1526835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Li-Fraumeni syndrome.
    Birch JM
    Eur J Cancer; 1994; 30A(13):1935-41. PubMed ID: 7734204
    [No Abstract]   [Full Text] [Related]  

  • 29. Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.
    Moule RN; Jhavar SG; Eeles RA
    Fam Cancer; 2006; 5(2):129-33. PubMed ID: 16736281
    [No Abstract]   [Full Text] [Related]  

  • 30. The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.
    Jhaveri AP; Bale A; Lovick N; Zuckerman K; Deshpande H; Rath K; Schwartz P; Hofstatter EW
    Yale J Biol Med; 2015 Jun; 88(2):181-5. PubMed ID: 26029016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is CHEK2 a cause of the Li-Fraumeni syndrome?
    Evans DG; Birch JM; Narod SA
    J Med Genet; 2008 Jan; 45(1):63-4. PubMed ID: 18178638
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hereditary breast cancers].
    Perey L; Schorderet DF
    Praxis (Bern 1994); 1996 Aug; 85(35):1035-9. PubMed ID: 8848674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
    Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
    J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes.
    Paules RS; Levedakou EN; Wilson SJ; Innes CL; Rhodes N; Tlsty TD; Galloway DA; Donehower LA; Tainsky MA; Kaufmann WK
    Cancer Res; 1995 Apr; 55(8):1763-73. PubMed ID: 7712486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of DNA diagnostics.
    Critchfield GC
    Dis Markers; 1999 Oct; 15(1-3):108-11. PubMed ID: 10595261
    [No Abstract]   [Full Text] [Related]  

  • 37. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
    Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A procedure for carrier detection in ataxia-telangiectasia.
    Takai S; Sanford KK; Tarone RE
    Cancer Genet Cytogenet; 1990 May; 46(1):139-40. PubMed ID: 2331679
    [No Abstract]   [Full Text] [Related]  

  • 39. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer.
    Taylor AM
    Br J Cancer; 1992 Jul; 66(1):5-9. PubMed ID: 1637676
    [No Abstract]   [Full Text] [Related]  

  • 40. Localizing the genes for ataxia-telangiectasia: a human model for inherited cancer susceptibility.
    Gatti RA
    Adv Cancer Res; 1991; 56():77-104. PubMed ID: 2028843
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.